Dapagliflozin Effects on Hypoglycemia

Part of paid clinical trials in La Jolla, California.

Sponsor
University of California, San Diego
Study ID
NCT03704818
Phase
PHASE1
Status
Completed

Conditions

  • Type1 Diabetes Mellitus

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Dapagliflozin 5mg — DRUG
    Dapagliflozin treatment taken daily for 4-weeks.
  • Placebo Oral Tablet — DRUG
    Placebo treatment taken daily for 4-weeks.

Study Details

The purpose of this research study will be to test and evaluate if dapagliflozin has an effect on the amount of glucagon (a hormone produced by the pancreas and stomach that stimulates liver glucose production) produced by the body and if that change will improve recovery time from hypoglycemia (low blood sugar) in participants with Type 1 Diabetes.

Key Dates

Start date
Oct 8, 2018
Status verified
Jan 2024
Primary completion
Jun 30, 2021
Completion
Nov 30, 2021

Study Design

Enrollment
22 participants (actual)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Experimental: Dapagliflozin 5mg
  • Experimental: Placebo

Primary Outcome Measure

Glucagon Response to Hypoglycemia [ Time Frame: 12 Weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
UC San Diego Altman Clinical & Translational Research InstituteLa JollaCalifornia92037-

Find similar trials in La Jolla, CA

By research site
UC San Diego Altman Clinical & Translational Research Institute· La Jolla, CA

Related Studies